大行評級|高盛:上調百濟神州ADR目標價至352.98美元 在慢性淋巴細胞白血病領域領導地位有望進一步鞏固
高盛發表報告,百濟神州在慢性淋巴細胞白血病(CLL)領域的領導地位有望進一步鞏固,其BTK/BCL2產品組合,包括BCL2抑制劑具顛覆一線CLL治療模式的巨大潛力,以及BTK降解劑初步反應數據令人鼓舞,且耐受性良好。基於相關樂觀看法,對百濟神州美國預託證券(ADR)及A股目標價上調至352.98美元及295.09元,投資評級“買入”。高盛預測,該藥物組合2035年經風險調整的銷售額爲88億美元,高於之前估算的72億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.